Biotech 360°

We capture this industry evolution with a strategy whose investments span throughout the entire value chain of drug development and not only limited to drug developers. The strategy focuses on tomorrow's new generation of tools & diagnostics techs, drugs, and life science services that could revolutionize the future of patient care. Such technologies include genetic medicines, cell therapy and liquid  biopsy.  The goal is precision medicine by which more efficient targeted therapies could reduce healthcare spending and possibly trigger a value-based industry. Artificial Intelligence will become key in molecule modeling.

Accurate diagnostic platforms render precision treatments possible while complex drugs will be increasingly manufactured by specialized outsourcing service companies.  The strategy invests in companies with robust and versatile technology platforms, which could disrupt massive markets such as cardiovascular, central nervous system and oncology, or address unique unmet medical needs such as orphan diseases.